Resource Summary

Clinical Question:
Is rosiglitazone a reasonable second or third line agent in the management of Type 2 Diabetes (DM2)?

Bottom-line:
Strong evidence supports increased cardiovascular risk^ specifically MI^ in Type 2 Diabetes patients receiving rosiglitazone. In the absence of any demonstrated patient oriented benefits^ there is no indication for its use.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2013-12-3
Last Updated on PCR: 2017-03-31 16:35:43